Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Saved in:
| Title: | Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML. |
|---|---|
| Authors: | Jaramillo, Sonia1 (AUTHOR) Sonia.jaramillosegura@med.uni-heidelberg.de, Krisam, Johannes2 (AUTHOR), Le Cornet, Lucian3 (AUTHOR), Kratzmann, Markus3 (AUTHOR), Baumann, Lukas2 (AUTHOR), Sauer, Tim1 (AUTHOR), Crysandt, Martina4 (AUTHOR), Rank, Andreas5 (AUTHOR), Behringer, Dirk6 (AUTHOR), Teichmann, Lino7 (AUTHOR), Görner, Martin8 (AUTHOR), Trappe, Ralf-Ulrich9 (AUTHOR), Röllig, Christoph10 (AUTHOR), Krause, Stefan11 (AUTHOR), Hanoun, Maher12 (AUTHOR), Hopfer, Olaf13 (AUTHOR), Held, Gerhard14 (AUTHOR), Buske, Sebastian15 (AUTHOR), Fransecky, Lars16 (AUTHOR), Kayser, Sabine3,17 (AUTHOR) |
| Source: | Trials. 11/3/2021, Vol. 22 Issue 1, p1-13. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
